Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies affecting mainly the middle aged and elderly. [1] [2] [3] The majority of affected patients die within 1-2 years due to overt leukemic transformation or the complication of cytopenias. The development of cytopenias despite the presence of cellular marrow is thought to be due to ineffective hematopoiesis probably associated with frequent apoptosis of hematopoietic cells. 4, 5 The mechanisms responsible for the disturbed hematopoiesis in MDS may include the expansion of abnormal clones, defects in cellular differentiation and the perturbed production of hematopoietic regulatory factors. In vitro examination revealed that the proliferation, as well as death, of hematopoietic cells is regulated by various proteins with stimulatory and inhibitory activities. 1 Colony-stimulating factors (CSFs) [6] [7] [8] [9] and several cytokines [7] [8] [9] [10] [11] are known to have proliferative effects on hematopoietic progenitor cells, while several substances such as tumor necrosis factor (TNF) 7, 8, [12] [13] [14] and interferons (IFNs) 13 were demonstrated to inhibit hematopoietic cell growth. Although the exact function of these substances in vivo has not yet been elucidated, overexpression of certain soluble factors by bone marrow cells may disrupt hematopoiesis by exerting profound inhibitory effects on hematopoietic progenitor cells. Actually, pancytopenia in aplastic anemia and hairy cell leukemia was shown to result from excessive production of lymphokines inhibitory to hematopoiesis. [15] [16] [17] In the bone marrow of patients with MDS, clonal disorders with trilineage dysplasia, interactions of abnormal clone cells with stromal cells including macrophages, fibroblastic cells and endothelial cells may be important for cytokine production. 18 Hematopoietic cells as well as stromal cells have been reported to express a wide range of substances which may play complex regulatory roles in hematopoiesis. [19] [20] [21] We have reported previously that the number of macrophage-lineage cells significantly increased in the bone marrow of MDS patients as compared with that of the control or de novo AML bone marrow. 22 Therefore not only the proliferation of MDS clone cells but also the abnormal function of stromal cells of the bone marrow may be involved in mechanisms causing cytopenias in MDS through disturbed regulation of the expression and production of growth factors and cytokines.
Recently, reverse transcriptase (RT)-polymerase chain reaction (PCR) amplification has proven to be a sensitive method for the detection of very low expression of mRNA from limited clinical samples. 23, 24 This study therefore attempted to investigate the disturbed regulatory mechanisms of hematopoiesis in MDS in vivo by defining up-regulation of inhibitory cytokine (TNF-␣ and IFN-␥) production using RT-PCR and then to immunohistochemically demonstrate the localization of the cytokine producing cells in the bone marrow.
Materials and methods

Patients
Fresh frozen bone marrow samples from 14 patients with MDS; five with refractory anemia (RA), three with RA with excess of blasts (RAEB), four with RAEB in transformation (RAEB-T) and two with chronic myelomonocytic leukemia (CMMoL) were investigated for the expression of cytokine mRNA (Table 1) . A diagnosis of MDS was based on FAB criteria. 1 None of the patients had received specific therapeutic Table 2 . Complementary (c)DNA was synthesized by using associated virus reverse transcriptase (Takara Biomedicals, Kyoto, Japan). The PCR reaction was performed as described elsewhere. 21, 23, 24 As a control reaction of PCR, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (196 bp) was also detected in each run. Briefly, 50 ng of the RNA was used for RT-PCR. For cDNA synthesis, 50 ng in 4 l of sample RNA solution was heated at 65°C for 5 min and cooled rapidly. After adding 20 U of ribonuclease inhibitor (Takara), 1 l of 1.25 mm dNTP (dATP, dCTP, dGTP, dTTP; Pharmacia, Uppsala, Sweden) and 20 U of Rous-associated virus reverse transcriptase (Takara), the mixture was incubated at 40°C for 30 min, then heated at 94°C for 5 min and cooled rapidly. The PCR reaction mixture contained 10 l of cDNA, 10 l of 10 × PCR buffer, 11 l of 20 mm MgCl 2 , 16 l of 1.25 m dNTP, 42.5 l of DEPC water, 100 pm 5Ј-and 3Ј-primer, and 2.5 U of thermostable Taq polymerase (Perkin Elmer Cetus, Norwalk, CT, USA). The amplification was achieved with a DNA thermal cycler (Perkin Elmer Cetus). After denaturing at 94°C for 10 min, the amplification was conducted for 35 cycles at 94°C for 30 s, 55°C for 30 s and 72°C for 60 s. This was followed by re-extension for 10 min at 72°C. Ten-microliter aliquots of the product samples were analyzed by electrophoresis on a 1.8% agarose gel and visualized by UV fluorescence after staining with ethidium bromide. X174/HaeIIIcut DNA was run in parallel as a molecular weight marker.
To study the specificity of RT-PCR, peripheral blood was collected from a normal human volunteer in preservative-free heparin. Ten milliliters of blood was adjusted to a volume of 30 ml by the addition of HBSS at pH 7.2, layered on a FicollHypaque gradient (Pharmacia) and centrifugated at 400 g for 30 min at 20°C. The supernatant was removed and the peripheral blood mononuclear cells (PBMC) in the interface were collected. The recovered PBMC was washed twice with 30 ml of HBSS and resuspended in RPMI 1640 containing 2.5 × 10 −5 m 2ME, penicillin, streptomycin, 2 mm glutamine The specific primers and probes were synthesized by the phosphoramide method using a DNA synthesizer based on RNA sequences published previously from GenBank.
and 5 mm HEPES buffer to a final concentration of 10 6 PBMC/ml. Next, 0.1 ml of cell suspension was placed in the wells of a 96-well microplate (Costar, Cambridge, MA, USA) and stimulated with 25 l of phytohemagglutinin (PHA) (Sigma Chemical Co, St Louis, MO, USA). After 24 h of incubation at 37°C in 5% humidified CO 2 , PBMC were collected and the RNA extraction was prepared as described previously. 24 To determine the sensitivity of the RT-PCR assay for the cytokine mRNA, 100 ng of RNA from PHA-stimulated PBMC was diluted with yeast RNA and assayed.
Southern blot analysis
The specificity of the amplified product was validated by its predicted size on an agarose gel and Southern blot analysis with a specific probe end-labeled with digoxigenin. Twenty microliters of each reaction mixture was run on composite gels containing agaroses in Tris/borate/EDTA(TBE) buffer. Gels were stained with ethidium bromide, photographed and transferred on to Zeta Probe membranes (BioRad, Richmond, CA, USA) by using an alkaline transfer technique. The membranes were hybridized with digoxigenin-labeled probe and after washing, incubated with peroxidase conjugated monoclonal anti-digoxigenin antibody. Bands in the washed membrane were detected by the enhanced chemiluminescence (ECL) system (Amersham Life Science, Buckinghamshire, UK). 
Results
Expression of mRNA for cytokines in the bone marrow
So as to examine very low levels of cytokine mRNA expression in bone marrow cells, RT-PCR was performed using RNA from frozen bone marrow tissues. This method revealed the expression of TNF-␣ mRNA, as defined by a 325 bp PCR product, in the bone marrow from patients with MDS. Control cases did not show any expression of TNF-␣ (Figure 1) . A dilution assay was carried out at the same time using the PHA-stimulated PBMC of the healthy volunteer. The detectable amount of TNF-␣ mRNA in our system was as low as 1 pg of total RNA from PHA-stimulated PBMC. This method is more sensitive than existing methods for detection of cytokines. Southern blot analysis was performed to confirm that the amplified PCR products were the cDNA of the TNF-␣ mRNA. As shown in Figure 2 , bone marrow samples from MDS patients showed strong expression of TNF-␣, whereas those from AML, CML and control cases showed no expression. The frequency of up-regulation of TNF-␣ mRNA in bone marrow samples is summarized in Table 3 . Most of the MDS cases expressed TNF-␣ mRNA (11/14, 79%), while none of the AML (0/6), CML (0/2) or control samples (0/8) showed signal. Differences in the frequency of TNF-␣ expression were statistically significant between MDS and control cases (Fisher's exact test, P Ͻ 0.001).
Positive RT-PCR signals for IFN-␥ mRNA were observed in some cases of MDS (5/12, 42%) ( Figure 1, Table 3 ) and the frequency of positive cases was higher than that of control cases (0/6). Among five MDS cases with IFN-␥ mRNA expression, all but one expressed TNF-␣ mRNA (4/5). Southern blot analysis showing the specificity of RT-PCR. Hybridization of PCR products with TNF-␣ probe was specifically observed in MDS cases, while bands for GAPDH were observed in all the samples.
Table 3
Frequency 
Distribution of cytokine-producing cells in the bone marrow of MDS patients
First, to show the histological distribution of bone marrow macrophages, CD68-positive cells were demonstrated on formalin-fixed paraffin-embedded tissue sections. As shown in Figure 3a (control), b (RA) and c (RAEB), the number of CD68-positive cells was greater in MDS bone marrow than in the bone marrow of control case.
As the mRNA of TNF-␣ was overexpressed in the bone marrow of MDS patients, distribution of TNF-␣-producing cells was examined by immunohistochemical method. As shown in Figure 4a , TNF-␣ was localized in scattered cells with irregular shaped cytoplasm. From their shape, these cells resembled bone marrow stromal cells and not hematopoietic cells. Thus, double immunostaining for TNF-␣ and CD68 antigen, a marker for macrophage-lineage cells, was performed on the frozen bone marrow sections. The staining clarified that the TNF-␣ producing cells were basically CD68-positive sug-
Figure 3
Immunohistochemical staining with anti-CD68 antigen monoclonal antibody on formalin fixed paraffin-embedded bone marrow sections from control case (a, ×210) and MDS cases (b: RA, ×210, c: RAEB, ×210). Note the increase in number of CD68-positive cells in the bone marrow from MDS patients compared to the number in control case.
gesting that these cells were mainly of bone marrow macrophage lineage (Figure 4b) . However, not all the CD68-positive cells were positive for anti-TNF-␣ staining indicating that the staining was specific. As shown in Figure 4c and d, a small number of IFN-␥-producing cells examined by double immunostaining were found to be of irregular shape and seemed to be stromal cells, although the reaction against INF-␥ was very weak in each case. Double immunostaining showed that these cells were also CD68-positive bone marrow macrophages.
Discussion
Hematopoiesis is controlled by a complex interplay of positive and negative feedback mechanisms mediated by multiple soluble factors including CFSs [6] [7] [8] [9] and cytokines such as IL-1, prostaglandin E2 (PGE 2 ), and lactoferrin 26 induce down-regulation of hematopoiesis by inhibiting the production of macrophage-derived granulomonopoietic enhancing activity. Bone marrow cells from MDS patients are known to have unbalanced growth characteristics [29] [30] [31] [32] but the underlying mechanisms causing them are still unclear. Recently, an increased frequency of apoptosis was observed in bone marrow cells of MDS patients. To clarify the mechanism of apoptosis induced in MDS, an in vivo study was performed to eliminate the influence of several of the growth factors in culture media. The present study clearly demonstrated that TNF-␣ or in some cases IFN-␥ production is specifically up-regulated in MDS bone marrow in vivo.
TNF-␣ is a protein produced by various cell types that was originally shown to induce necrosis and/or apoptosis of tumor cells in vivo. 33 TNF-␣, alone or in synergy with IFN-␥, has been described as an inhibitor of in vitro [12] [13] [14] and in vivo hematopoiesis. 8, 15, 34 However, a recent study has revealed that TNF-␣ strongly potentiates IL-3 and granulocyte-macrophage (GM) CSF-induced growth of CD34-positive human hematopoietic progenitor cells, when well-differentiated cells are present in the culture. 11 The effect of TNF-␣ on hematopoiesis may well depend on the complex state of disturbed maturation of hematopoietic cells, ie cytopenias in spite of the presence of cellular marrow, seen in MDS. Recently, serum TNF-␣ levels have been found to be increased in MDS patients. 4 They showed that TNF-␣ levels were inversely correlated with lower levels of hemoglobin concentration, 35 were predictors for conversion to acute leukemia 36 and were related to clinical response to therapy with recombinant erythropoietin. 37 Further, immunohistochemical staining has revealed that many bone marrow cells were positively stained with anti-TNF-␣ antibody in MDS cases. 4, 38 Although these findings were not direct evidence of TNF-␣ production in vivo, they are consistent with the results presented here.
Some authors point to a correlation of disturbed growth of CFU-GM with abnormal production of CFS in MDS, 29, 30 while others propose that leukemia-associated inhibitory activity contributes to the development of the disease processes in MDS. 31, 32, 35 Among several substances which have inhibitory effects on hematopoiesis, increased production of ferritin and PGE 2 have been found in bone marrow cultured cells from MDS patients. 1, 39 In vivo administration of ferritin to mice significantly decreased marrow cellularity and peripheral blood nucleated cell count, 28 although BM in MDS are usually normo-or hypercellular. Therefore, ferritin is not responsible for cytopenias in MDS. Infection with viruses, such as immunodeficiency viruses, induces hematological abnormalities including myelodysplasia. 40 TNF-␣ from bone marrow cells is a potential inhibitory factor of hematopoiesis after viral infection. 10 Increased levels of TNF-␣ production are observed in serum from AIDS patients and simian immunodeficiency virus (SIV)-infected monkeys. These results are consistent with the findings that SIV infection of bone marrow macrophages correlated with the incidence of hematological abnormalities in vivo. 40 Thus, we could point out the possibility that the overexpression of TNF-␣ and occasionally IFN-␥, may contribute to the ineffective hematopoiesis and dysplasia of the bone marrow in MDS patients.
